U.S. Communications Stock News

NYSE:KBH
NYSE:KBHConsumer Durables

Is KB Home (KBH) Using New ENERGY STAR Communities To Recast Its Build‑To‑Order Strategy?

KB Home recently opened several new communities across the U.S., including Stevens Ridge in Marysville, Washington, Sunset Oaks and Madera in Texas, and multiple developments in California and Arizona, offering personalized, ENERGY STAR®-designed homes with prices starting from the mid US$200,000s to the US$590,000s range. These geographically diverse launches, all emphasizing efficiency, health-focused features and extensive buyer personalization, highlight KB Home’s continued push into...
NasdaqGS:OTEX
NasdaqGS:OTEXSoftware

Does Open Text (OTEX) Tighten Its Focus or Shrink Its Ambition With Vertica Sale And Steady Guidance?

In early May 2026, Open Text Corporation reported third-quarter results showing higher revenue of US$1,282.5 million and net income of US$172.65 million year-on-year, affirmed its 2026 earnings guidance for 1% to 2% revenue growth after adjusting for US$30 million of divested sales, completed the sale of its Vertica business, and confirmed a quarterly dividend of US$0.2750 per share payable on June 19, 2026. By exiting the non-core Vertica analytics unit and directing the proceeds toward...
NasdaqCM:ALOY
NasdaqCM:ALOYSoftware

Assessing REalloys (ALOY) Valuation After Full-Year Losses And Updated Going Concern Outlook

REalloys (ALOY) has moved into focus after a cluster of filings, including full year 2025 results showing US$0.8 million in sales, a US$75.6 million net loss, and management’s updated view on its going concern status. See our latest analysis for REalloys. Since those filings, REalloys’ share price has come under pressure, with a 7 day share price return down 12.64% and a 30 day share price return down 32.55%. The 1 year total shareholder return is very large, which suggests earlier optimism...
NasdaqGS:ERAS
NasdaqGS:ERASBiotechs

Assessing Erasca (ERAS) Valuation After ERAS-0015 Patent And Trade Secret Dispute

Erasca (ERAS) is under pressure after disclosing that Revolution Medicines accused its lead candidate ERAS-0015 of patent infringement and trade secret misappropriation, prompting multiple securities law investigations and raising fresh questions about the program’s long term prospects. See our latest analysis for Erasca. The latest legal headlines arrive after a sharp 43.79% decline in the 30 day share price return. This follows a strong year to date share price return of 184.96% and a very...
NYSE:WELL
NYSE:WELLHealth Care REITs

How Investors May Respond To Welltower (WELL) Raising 2026 Guidance On Stronger Occupancy And NOI

Earlier in Q2 2026, Welltower reported strong Q1 results, with revenue rising about 40%, senior housing same-store NOI up sharply, and portfolio occupancy improving to roughly 89%, prompting management to raise full-year 2026 normalized FFO guidance while keeping its payout ratio under 50%. This combination of faster growth and a conservative payout suggests management sees room to support dividends while continuing to invest across its healthcare real estate platform. We’ll now explore how...
NasdaqGS:BCRX
NasdaqGS:BCRXBiotechs

European Navenibart Deal And Reaffirmed 2026 Outlook Could Be A Game Changer For BioCryst (BCRX)

In early May 2026, BioCryst Pharmaceuticals reported first-quarter revenue of US$156.41 million but a net loss of US$721.81 million, while maintaining full-year 2026 revenue guidance of US$635 million to US$660 million and announcing a European licensing deal for navenibart that includes a US$70 million upfront payment plus potential milestones and royalties. The navenibart agreement with Neopharmed Gentili’s Irish affiliate both brings immediate capital to BioCryst and outsources European...
NasdaqGS:BIIB
NasdaqGS:BIIBBiotechs

Biogen’s Diranersen Moves To Late-Stage Alzheimer’s Trials And Investor Focus

Biogen (NasdaqGS:BIIB) is advancing its experimental Alzheimer’s drug diranersen into late stage trials after Phase 2 CELIA data. The therapy, an antisense oligonucleotide that targets tau protein, did not meet the study’s primary endpoint but showed strong biomarker changes and signs of cognitive benefit. The decision extends Biogen’s Alzheimer’s efforts beyond amyloid focused treatments and increases attention on its neurology pipeline. For you as an investor, this keeps Biogen in the...
NYSE:MSA
NYSE:MSACommercial Services

Assessing MSA Safety (MSA) Valuation After Recent Share Price Volatility

MSA Safety stock snapshot after recent moves MSA Safety (MSA) has drawn fresh attention after recent price swings, with the stock closing at US$171.24. For investors, the question now is how current valuation aligns with fundamentals. See our latest analysis for MSA Safety. Recent trading has been choppy, with the share price falling 15.2% over the past 90 days but still showing a 5.55% year to date share price return and 8.68% one year total shareholder return. This suggests moderating...
NYSE:GNK
NYSE:GNKShipping

Genco Rejects Diana Tender Offer As Control And Governance Battle Escalates

Genco Shipping & Trading (NYSE:GNK) has rejected an unsolicited tender offer from Diana Shipping Inc. The board voted unanimously against the bid and is urging shareholders not to tender their shares. The rejection comes during an active takeover and proxy contest focused on control, valuation, and governance. For investors watching NYSE:GNK, this board level pushback follows a strong run in the stock, with shares up 33.6% year to date and 82.7% over the past year, closing at $24.63. The...
NYSE:AIT
NYSE:AITTrade Distributors

Does Slower Organic Growth Undermine the Automation and M&A Story at Applied Industrial Technologies (AIT)?

In recent commentary, Applied Industrial Technologies has been flagged for underperformance in its core business, with organic revenue and earnings growth over the past two years trailing industry peers and highlighting a heavier dependence on acquisitions to sustain expansion. This weaker internal growth profile, combined with only modestly projected sales improvement, raises questions about how effectively Applied can balance acquisition-driven growth with the health of its underlying...
NasdaqGS:ROKU
NasdaqGS:ROKUEntertainment

Is It Too Late To Consider Roku (ROKU) After Its 73.8% One Year Surge?

If you are wondering whether Roku at around US$124.02 is still priced fairly after its recent run, you are not alone in questioning what the current share price really reflects. The stock has pulled back about 4.3% over the last week, although it is still up 13.4% over the past month, 14.1% year to date, and 73.8% over the last year. The 3 year return sits at 135.7% and the 5 year return shows a decline of 62.5%. Recent headlines around Roku have focused on its positioning in streaming, its...
NYSE:HTH
NYSE:HTHBanks

A Look At Hilltop Holdings (HTH) Valuation After Mixed Recent Share Price Performance

Hilltop Holdings: Recent Performance Snapshot Hilltop Holdings (HTH) has been trading around its recent close of US$36.29, with the stock down about 2% over the past month and roughly 8% over the past 3 months. Despite this pullback, the stock shows a total return of about 20% over the past year and around 25% over the past 3 years, with year-to-date performance near 7%. See our latest analysis for Hilltop Holdings. Recent share price weakness, with the 90 day share price return down 7.6%,...
NYSE:SWK
NYSE:SWKMachinery

Is Stanley Black & Decker (SWK) Offering Value After Its Recent 11.8% Share Price Move

Wondering whether Stanley Black & Decker stock at around US$75 is giving you value or asking too much? Price is only half the story; the real question is what you are getting for it. Over the last month the share price has risen 11.8%, yet it is still down 1.7% year to date and up 10.2% over the past year, which can leave the stock looking very different depending on your time frame. Recent coverage has focused on how the stock's multi year performance, including a 3 year return of 3.8% and...
NasdaqGS:JBHT
NasdaqGS:JBHTTransportation

Supreme Court Ruling Puts Spotlight On J.B. Hunt Valuation And Momentum

U.S. Supreme Court rules that freight brokers can be held liable for damages in trucking incidents. Ruling is seen as supportive of J.B. Hunt Transport Services' vertically integrated trucking and logistics model. Decision may increase legal and compliance risks for asset light brokers that do not operate their own fleets. J.B. Hunt Transport Services, listed as NasdaqGS:JBHT, sits in a different position from many freight brokers because it combines trucking assets with logistics...
NYSE:CMS
NYSE:CMSIntegrated Utilities

What CMS Energy (CMS)'s New US$3 Billion At-the-Market Equity Program Means For Shareholders

Earlier this week, CMS Energy Corporation approved amendments at its May 8, 2026 annual meeting and launched a US$3.00 billion at-the-market common equity program, while shareholders rejected a proposal to allow action by written consent. This combination of expanded authorized shares, new equity issuance capacity and preserved limits on shareholder-initiated actions materially reshapes CMS Energy’s governance and capital structure flexibility. We’ll now examine how CMS Energy’s new US$3.00...
NasdaqGS:HSIC
NasdaqGS:HSICHealthcare

A Look At Henry Schein (HSIC) Valuation After Solid Q1 Update And Reaffirmed Guidance

Henry Schein (HSIC) stock is in focus after first quarter results highlighted steady U.S. dental and technology performance, reaffirmed full year guidance, and an industry report that places clinical execution, not scale, at the center of practice growth. See our latest analysis for Henry Schein. Henry Schein’s recent Q1 update, reaffirmed 2026 outlook and ongoing buybacks have supported sentiment. However, the stock’s 30 day share price return is down 6.07% and its 1 year total shareholder...
NasdaqGM:GUTS
NasdaqGM:GUTSMedical Equipment

Fractyl Health (GUTS) Is Up 14.0% After RJVA-001 Human Trial Nod And Q1 Profitability Shift – Has The Bull Case Changed?

In May 2026, Fractyl Health reported first-quarter 2026 net income of US$9.22 million, reversing a prior-year loss, and secured authorization in the Netherlands to begin a Phase 1/2 first-in-human trial of RJVA-001, its Smart GLP-1 gene therapy candidate for type 2 diabetes. An important detail for investors is that this regulatory clearance makes Fractyl a dual clinical-stage company, advancing both its Revita procedure for post‑GLP‑1 weight maintenance and its Rejuva gene therapy platform...
NasdaqGS:PRGS
NasdaqGS:PRGSSoftware

Progress Software Award Spotlights Agentic RAG And Undervalued AI Potential

Progress Software (NasdaqGS:PRGS) has received a 2026 Artificial Intelligence Excellence Award for its Agentic RAG platform. The award recognizes the platform in the Retrieval Augmented Generation (RAG) category for its role in AI driven data solutions. Agentic RAG focuses on converting unstructured data into governed intelligence for enterprise use. For you as an investor, this award draws attention to how Progress Software is positioning itself around operational AI rather than only...